Nutraceuticals to Improve Lipid Profile in European Countries
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Cardiovascular prevention include a class I indication to statins in addition to
non-pharmacologic intervention and prevention strategies in patients deemed to be 'high risk'
according to current scientific guidelines. In the real world, however, statin treatment is
often discontinued due to side effects.
In addition, statins are not indicated in those subjects deemed to be 'low risk', in whom
only non-pharmacologic intervention and prevention strategies are currently prescribed.
Along with non-pharmacologic intervention and prevention strategies, newer approaches to
reduce cholesterol blood levels currently include nutraceuticals, which are compounds derived
from foods with cholesterol lowering actions.
The primary objective of this study is twofold:
First, to prospectively compare in the real world clinical practice the efficacy and
tolerability of non-pharmacologic intervention vs. the combination of non-pharmacologic
intervention with a nutraceutical-based protocol in patients in whom statin treatment is not
tolerated or is not indicated.
Second, to evaluate gender and race/ethnic differences in the hypolipidemic effects of a
nutraceutical-based protocol among European countries.